Wave Life Sciences, Inc. (WVE): Capital Expenditures
$718.0K
Year ended 2025-12-31
$1.57M
Trailing 12 months to 2026-06-30
-19.2%
3-year compound annual growth
-11.7%
5-year compound annual growth
-9.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $718.0K | -23.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $938.0K | -15.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.11M | -18.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $1.36M | +143.0% | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $560.0K | -58.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $1.34M | -65.8% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $3.92M | -60.6% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $9.94M | -47.4% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $18.89M | +239.3% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $5.57M | +199.8% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $1.86M | +214.7% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $590.0K | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $47.0K | n/a | 2016-03-30, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $718.0K | -23.5% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $518.0K | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $2.0K | -80.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $562.0K | +253.5% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $518.0K | -75.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.59M | +17.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $1.57M | +552.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
Compare WVE, XLO, BFRI, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗